All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Permethrin (PERM) is a pesticide belonging to the pyrethroid family that has been used to induce Parkinson's disease (PD) in an animal model. In our previous studies, neonatal rats treated daily per o.s. for 2 weeks with permethrin (34 mg/kg body weight) developed the three pathological hallmarks of PD: namely loss of dopaminergic neurons in the substantia nigra, increase of free and aggregated alpha-synuclein protein levels reminiscent of Lewy bodies and motor and non-motor symptoms correlated with PD \[[@pone.0223238.ref001]\], \[[@pone.0223238.ref002]\], \[[@pone.0223238.ref003]\], \[[@pone.0223238.ref004]\]. Successively, we observed that the co-treatment with electrochemically reduced water (ERW), a hydrogen-rich water buffered to pH 7.4, was able to protect against damage on dopaminergic neurons induced by permethrin treatment \[[@pone.0223238.ref005]\]. The ERW is a water supersaturated with active hydrogen produced near the cathode during electrolysis of water. It is a functional drinking water with highly dissolved molecular hydrogen (0.4--0.9 ppm) and extremely negative oxidative redox potential (ORP) values (-300 mV) that possesses reactive oxygen species (ROS)-scavenging activity conferred by the effect of dissolved H~2~ \[[@pone.0223238.ref006]\].

In recent years, it has become clear that PD is associated with a number of gastrointestinal symptoms such as constipation originating from functional and structural changes in the gut and its enteric nervous system. These disturbances happen years before the development of motor symptoms and diagnosis of PD and may therefore provide important insights into the origin and development of the disease. There is accumulating evidence that the origin of the disease may lie in the gut with possible involvement of misfolded alpha-synuclein deposits observed in the enteric nervous system. Furthermore, alterations of gut microbiota composition, local inflammation and increased gut permeability have been shown in PD patients. Environmental factors such as exposure to pesticides seem to play a key role to initiate the pathophysiological cascade in PD. One proposed pathway is the disruption of gut microbiome composition and subsequent development of intestinal inflammation with retrograde ascension up the vagus nerve to reach the central nervous system \[[@pone.0223238.ref007]\], \[[@pone.0223238.ref008]\], \[[@pone.0223238.ref009]\]. It has been postulated that the enteric nervous system (ENS) is affected early during the progression of PD even before the substantia nigra, therefore supporting a key role for the ENS in the initiation and spreading of PD pathological process, although this hypothesis remains currently controversial.

Recent studies conducted in PD patients have demonstrated a shift of microbiota composition to a proinflammatory state related with higher lipopolysaccharide (LPS) levels \[[@pone.0223238.ref010]\]. Moreover, lower serum levels of LPS-binding protein (LBP) were found in PD patients which is indicating higher systemic LPS exposure \[[@pone.0223238.ref011]\]. The gut dysbiosis induces overstimulation of the innate immune system via TLR signalling and provokes local and systemic inflammation triggering the development of alpha-synuclein pathology \[[@pone.0223238.ref012]\], \[[@pone.0223238.ref013]\].

In the light of these premises, in this study, we intended to explore whether in our PD animal model there were changes in gut permeability, fecal microbiota composition and histological hallmarks of hepatic injury. Moreover, we tested if the co-treatment with ERW was effective to counterbalance gut alterations induced by PERM pesticide in the PD animal model.

Materials and methods {#sec002}
=====================

The study was carried out in strict accordance with the European Guidelines (Directive 2010/63/EU) for the Care and Use of Laboratory Animals. The protocol was approved by the Italian Ministry of Health (Protocol Number: 393/2016-PR). All efforts were made to minimize suffering.

Materials {#sec003}
---------

Technical grade (75:25, trans:cis; 94% purity) 3-phenoxybenzyl-(1R,S)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxyl-ate, PERM (PubChem CID: 40326) were generously donated by Dr. A. Stefanini of ACTIVA (Milan, Italy). Corn oil, citric acid, fluorescein isothiocyanate---dextran 4 kDa (FITC-dextran), 3,3',5,5'-tetramethylbenzidine, hexadecyltrimethylammonium bromide, naphthol ASD-chloroacetate esterase kit were obtained from Sigma (Milan, Italy). 3,3′-diaminobenzidine (DAB) was purchased from DAKO (Hamburg, Germany). Periodic acid (1%), protease mixture and BSA were purchased from Carl Roth (Karlsruhe, Germany). Alcian blue 8GS was purchased from Serva (Heidelberg, Germany).

Animals and treatments {#sec004}
----------------------

Male and female Wistar rats aged about 90 days weighing 250--270 g were obtained from Charles River (Calco, LC, Italy). Animals were housed in a room with artificial 12:12 h light/dark cycle (lights off at 8:00 a.m.), at constant temperature (21±5°C) and humidity (45--55%). Food and water were always available in the home cages. Male rat pups born in our laboratory from primiparous dams were assigned to three treatment groups (n = 20 PERM-treated rats, n = 18 controls and n = 20 PERM+ERW-treated rats) so that each group contained no more than 3 pups from any litter. At the time of weaning, rats were housed in single cages to avoid coprophagic behavior that leads to a confluence of the microbial populations among cage mates. The first group was treated once daily by gavage with PERM (34 mg/4 mL/kg body weight) from postnatal day (PND) 6 to PND 21, whereas the second group (control) was treated with the vehicle (corn oil 4 mL/kg body weight) on a similar schedule. PERM was prepared by dissolving the substance in the corn oil as previously described \[[@pone.0223238.ref014]\].

A third group was gavaged once a day with PERM (34 mg/4 mL/kg body weight) and co-treated twice a day (early morning and late afternoon) with ERW (10 mL/kg body weight) from PND 6 to PND 21. ERW was produced by a water ionizer and buffered with citric acid at a pH = 7.4 before use. On PND 60, animals were divided in two batches: one was submitted to *in vivo* intestinal permeability assay and the second was sacrificed by CO~2~ asphyxiation and the tissues were submitted to analysis.

Preparation of electrolyzed reduced water {#sec005}
-----------------------------------------

ERW was produced by a continuously electrolyzing device (Chanson Revolution 9 plates, Taiwan), wherein tap water is the water source. The device is composed of two units, a micro-carbon cartridge unit for removal of contaminants from tap water and an electrolysis unit that acts on the purified water. The latter passed through a micro-carbon cartridge unit and flows into the electrolysis unit, which is composed of platinum-coated electrode plates, separated by semi-permeable membranes and the water is electrolyzed while passing through the gaps between the electrodes. ERW is a functional drinking water characterized by a high pH (around 9.5--10), a low amount of dissolved oxygen, a low redox potential (ORP = -300 mV) and a high concentration of dissolved H~2~ (0.4--0.9 ppm) compared with tap water (pH = 7.4, ORP = +300 mV and H~2~ = 0 ppm) that confers antioxidant activity to the water as reported by other studies \[[@pone.0223238.ref015]\], \[[@pone.0223238.ref016]\].

In vivo intestinal permeability assay {#sec006}
-------------------------------------

A first batch of rats, overnight fasted, from control (n = 8), PERM-treated (n = 10) and PERM+ERW-treated (n = 10) groups was assayed for gut permeability with FITC-dextran on PND 60. The low-molecular-weight fluorescent marker FITC-dextran powder was dissolved in pure water to a concentration of 100 mg/mL. Induction of anesthesia was achieved with 5% [isoflurane](https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/isoflurane) in oxygen that the animals were breathing spontaneously through a gas anesthesia mask. The first blood sample was collected, from the tail of anesthetized rats (5% isoflurane), immediately prior to administration of FITC-dextran, as a negative control for plasma background fluorescence. The rats were then orally dosed with FITC-dextran solution (500 mg/kg body weight). Two hours after dosage, animals were anesthetized and blood was collected from the tail directly into tubes containing sodium heparin (5 μL). Blood samples were immediately centrifuged (2,000 g force, 5 min) to collect plasma that was diluted 3:1 in PBS. A calibration curve for FITC-dextran in plasma was build and fluorescence intensities of samples were measured by spectrofluorometer Hitachi F-4500 using 485 and 528 nm as excitation and emission wavelengths, respectively.

Dopamine assessment in striatum nucleus {#sec007}
---------------------------------------

Tissues derived from the rat striatum were homogenized with 500 μL of 1N perchloric acid solution containing 0.02% w/v sodium metabisulphite and 0.05% w/v disodium ethylenediaminetetraacetate (Na2EDTA). Samples were centrifugated at 4500 x g for 20 min at 4°C. The obtained supernatants were filtered using 0.45 um filters, collected into vials and stored on ice until analysis. 10 μL of the filtrate was analyzed by HPLC (Rheodyne 7295 injector and Antec Leyden Decade II detector) as reported in Bordoni et al. \[[@pone.0223238.ref003]\]. Final values were expressed as ng/mg tissue.

Histological and immunohistochemical stainings {#sec008}
----------------------------------------------

From a second batch of control (n = 10), PERM-treated (n = 10) and PERM+ERW-treated (n = 10) rats, fecal pellets were freshly collected on PND 60, and stored at -80°C until analysis to quantify bacterial population and short-chain fatty acids (SCFA). On the same day, animals were killed by CO~2~ asphyxiation. Samples of liver and intestine (duodenum, ileum and colon) were excised, washed briefly with phosphate-buffered saline (pH 7.4), fixed in 10% buffered formalin for 48 h and embedded in paraffin. The remaining tissues were frozen in liquid nitrogen and stored at -80°C.

Paraffin embedded liver tissue was cut (4 μm), deparaffinized and stained with hematoxylin and eosin. Tissue sections were scored as described by Kleinert et al. \[[@pone.0223238.ref017]\]. Using a microsope (Leica, Wetzlar, Germany), number of neutrophils in liver sections was assessed by staining liver sections with chloroacetate esterase (naphthol ASD-chloroacetate esterase kit, Sigma-Aldrich) as previously detailed \[[@pone.0223238.ref018]\]. For detection of iNOS protein in liver tissue, liver sections were treated as previously described in detail \[[@pone.0223238.ref018]\]. In brief, sections were incubated with a polyclonal antibody against iNOS (dilution 1: 2250; Thermo Fischer Scientific, Waltham USA) overnight followed by an incubation with a secondary peroxidase-linked antibody and diaminobenzidine (Peroxidase Envision Kit, DAKO, Hamburg, Germany). The extent of staining in tissue sections was defined as percentage of the field area within the default color range determined by the software using an image acquisition and analysis system incorporated in the microscope (Leica DM4000 B LED, Germany). To determine means, data from 8 fields of each tissue section were used (200 x magnification).

For tissue-specific localization of tight junction proteins in sections of duodenum, ileum and colon (4 μM) immunohistochemical staining of zonula occludens 1 (ZO-1) and occludin was performed as previously reported \[[@pone.0223238.ref018]\]. In brief, sections were incubated with a polycolonal antibody (anti-ZO-1 or anti-occludin both Life Technologies, Darmstadt, Germany) overnight. Sections were than incubated with a secondary peroxidase-linked antibody and diaminobenzidine (Peroxidase Envision Kit, DAKO, Hamburg, Germany). The extend of staining in tissue sections was determined as detailed above using 8 fields of each tissue section to determine means (400 x magnification).

To assess number of mucus-producing Goblet cells in duodenum, ileum and colon tissue sections were stained with Alcian blue/periodic acid-Schiff as previously described \[[@pone.0223238.ref019]\]. Number of Goblet cells were counted in 10 microscopic fields (400 x magnification) and shown as means.

Measurement of liver myeloperoxidase (MPO) activity {#sec009}
---------------------------------------------------

MPO activity was measured photometrically employing 3,3',5,5'-tetramethylbenzidine as substrate as detailed before by us and others \[[@pone.0223238.ref020]\], \[[@pone.0223238.ref021]\].

SCFA in feces {#sec010}
-------------

Levels of acetic, propionic, and butyric acids were detected in feces of rats at PND 60. Ten feces samples for each rat group (one feces sample for each rat) were analyzed by headspace solid-phase microextraction coupled to gas-chromatography equipped with flame ionization detection as previously reported \[[@pone.0223238.ref022]\]. Triplicates of each homogenized sample were analyzed and results were expressed as μmol/g feces.

Fecal microbiota analyses {#sec011}
-------------------------

Fecal samples collected at PND 60 from control (n = 10), PERM-treated (n = 10) and PERM+ERW-treated (n = 10) groups were evaluated using 16S rRNA gene sequencing to determine the composition of the fecal bacterial populations.

Partial 16S rRNA gene sequences were amplified from extracted DNA using primer pair Probio_Uni and /Probio_Rev, which target the V3 region of the 16S rRNA gene sequence \[[@pone.0223238.ref023]\]. 16S rRNA gene amplification and amplicon checks were carried out as previously described \[[@pone.0223238.ref023]\]. 16S rRNA gene sequencing was performed using a MiSeq (Illumina) at the DNA sequencing facility of GenProbio srl ([www.genprobio.com](http://www.genprobio.com/)) according to the protocol previously reported \[[@pone.0223238.ref023]\]. Following sequencing, the obtained individual sequence reads were filtered by the Illumina software to remove low quality and polyclonal sequences. All Illumina quality-approved, trimmed and filtered data were exported as .fastq files. The .fastq files were processed using a custom script based on the QIIME software suite \[[@pone.0223238.ref024]\]. Paired-end reads pairs were assembled to reconstruct the complete Probio_Uni / Probio_Rev amplicons. Quality control retained sequences with a length between 140 and 400 bp and mean sequence quality score \>20 while sequences with homopolymers \>7 bp and mismatched primers were omitted. In order to calculate downstream diversity measures (alpha and beta diversity indices, Unifrac analysis), 16S rRNA Operational Taxonomic Units (OTUs) were defined at ≥ 97% sequence homology using uclust \[[@pone.0223238.ref025]\]. All reads were classified to the lowest possible taxonomic rank using QIIME \[[@pone.0223238.ref024]\] and a reference dataset from the SILVA database \[[@pone.0223238.ref026]\]. Biodiversity of the samples (alpha-diversity) were calculated with Chao1 and Shannon indexes measured at 47746 reads \[[@pone.0223238.ref027]\]. Similarities between samples (beta-diversity) were calculated by unweighted uniFrac \[[@pone.0223238.ref028]\]. The range of similarities is calculated between the values 0 and 1. PCoA representations of beta-diversity were performed using QIIME \[[@pone.0223238.ref024]\]. Hierarchical clusterings were performed with TMeV 4.8.1 ([http://www.tm4.org](http://www.tm4.org/)) using Pearson correlation.

Statistical analysis {#sec012}
--------------------

Statistical analysis was carried out using the program Statistica 8.0 (StatSoft Italy Srl, Vigonza, Italy, 2007). Data were analysed using an one-way ANOVA followed by post hoc Newman-Keuls test. Since data were not normally distributed, a non-parametric Kruskal-Wallis test was employed. Differences were considered significant at a P-value of 0.05.

Results {#sec013}
=======

Evaluation of intestinal permeability with FITC-dextran {#sec014}
-------------------------------------------------------

At PND 60, a first batch of control, PERM-treated and PERM+ERW-treated rats was tested for FITC-dextran concentration in plasma in order to assess intestinal permeability. One way ANOVA revealed significant differences (F~(2,25)~ = 3.41, P\<0.05) in FITC-dextran concentration among the three groups ([Fig 1A](#pone.0223238.g001){ref-type="fig"}). Post hoc comparisons revealed a significant increased intestinal permeability in PERM-treated rats compared to the control group (P\<0.05), whereas no difference was observed between PERM+ERW-treated rats and control ones (P\>0.05). These results showed that early life exposure to PERM, in rats aged 60 days, altered permeability to FITC-dextran and the co-treatment with ERW improved intestinal barrier integrity.

![**Plasma FITC-dextran concentrations (ng/mL) (A) and striatum dopamine levels (B) in 2-months-old rats treated in early life with vehicle (control), permethrin (PERM) or permethrin+electrolyzed reduced water (PERM+ERW).** The increase of intestinal permeability and the decrease of striatum dopamine levels in the PERM group were improved by co-treatment with ERW. All data are expressed as means ± SEM. Group sizes in A: control (n = 8), PERM (n = 10) and PERM+ERW (n = 10), \*P\<0.05. Group sizes in B: n = 6 rats per group, \*\*P\<0.01.](pone.0223238.g001){#pone.0223238.g001}

Dopamine levels in striatum nucleus {#sec015}
-----------------------------------

At PND 60, dopamine levels were measured in striatum nucleus of control, PERM-treated and PERM+ERW-treated rats. One way ANOVA revealed significant differences (F~(2,15)~ = 14.94, P\<0.01) in dopamine levels among the three groups ([Fig 1B](#pone.0223238.g001){ref-type="fig"}). Post hoc comparisons revealed a significant decreased dopamine levels in striatum of PERM-treated rats compared to the control group (P\<0.01) as previously reported \[[@pone.0223238.ref001]\], \[[@pone.0223238.ref002]\], \[[@pone.0223238.ref003]\], \[[@pone.0223238.ref014]\]. The co-treatment with ERW increased the dopamine levels that were similar to those of control rats (P\>0.05). The results suggested that early life exposure to PERM, in rats aged 60 days, altered dopamine levels in striatum and the co-treatment with ERW could protect against the neurodegeneration.

Histological findings in liver and MPO activity {#sec016}
-----------------------------------------------

While rats treated with PERM displayed significantly more signs of hepatic inflammation, e.g. inflammatory foci, than animals treated with PERM+ERW or control animals (P\<0.05 for both), the nonalcoholic fatty liver disease activity score (NAS) between control and PERM+ERW-treated rats was similar. In line with these findings, the number of neutrophils was also higher in livers of PERM-treated animals than in those of controls and PERM+ERW-treated rats (P\<0.05 for both). However, as data varied considerable within groups, activity of MPO in liver tissue did not differ among groups (P\>0.05). Data are reported in [Table 1](#pone.0223238.t001){ref-type="table"} and [Fig 2A](#pone.0223238.g002){ref-type="fig"}.

![**Representative stainings of liver (A) and intestinal (B) sections in 2-month-old rats treated in early life with vehicle (control), permethrin (PERM) or permethrin+electrolyzed reduced water (PERM+ERW) from left to right, respectively (100X, 200X and 400X magnification).** In **A**: a) hematoxylin-eosin staining with clusters (aggregates) of inflammatory cells indicated by arrows; b) infiltration of activated neutrophils assessed by staining chloroacetate esterase. Arrows indicate neutrophils; c) immunohistochemical detection of iNOS expression. In **B**: immunohistochemical detection of occludin in d) duodenum and e) ileum; and ZO-1 in f) duodenum and g) ileum.](pone.0223238.g002){#pone.0223238.g002}

10.1371/journal.pone.0223238.t001

###### Scores measured in liver (L), duodenum (D), ileum (I), colon (C) and feces (F) of 2-months-old rats treated in early life with vehicle (C), permethrin (PERM) or permethrin+electrolyzed reduced water (PERM+ERW).

![](pone.0223238.t001){#pone.0223238.t001g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                         C                     PERM                  PERM+ERW                                C *vs* PERM                                 PERM *vs* PERM+ERW                        C *vs* PERM+ERW
  ---------------- --------------------- --------------------- --------------------- --------------------------------------- ------------------------------------------- ----------------------------------------- ---------------------------------------
  L                Inflammation\         0.31±0.09             0.98±0.04             0.57±0.04                               [\*\*\*](#t001fn004){ref-type="table-fn"}   [\*](#t001fn002){ref-type="table-fn"}     
                   (NAS)                                                                                                                                                                                           

  Neutrophils\     2.05±0.47             3.36±0.49             1.83±0.37             [\*](#t001fn002){ref-type="table-fn"}   [\*](#t001fn002){ref-type="table-fn"}                                                 
  (n. per MF)                                                                                                                                                                                                      

  iNOS activity\   3.56±0.35             6.77±0.55             2.34±0.37             [\*](#t001fn002){ref-type="table-fn"}   [\*\*\*](#t001fn004){ref-type="table-fn"}                                             
  (% per MF)                                                                                                                                                                                                       

  MPO activity\    2.8x10^-3^±3x10^-4^   6.5x10^-3^±3x10^-3^   2.7x10^-3^±2x10^-4^                                                                                                                                 
  (A/mg protein)                                                                                                                                                                                                   

  D                Occludin\             8.59±0.91             5.11±0.82             5.85±0.84                               [\*](#t001fn002){ref-type="table-fn"}                                                 
                   (% per MF)                                                                                                                                                                                      

  ZO-1\            17.02±2.85            7.59±1.99             5.04±0.46             [\*](#t001fn002){ref-type="table-fn"}                                               [\*\*](#t001fn003){ref-type="table-fn"}   
  (% per MF)                                                                                                                                                                                                       

  Goblet cells\    0.03±3x10^-3^         0.03±3x10^-3^         0.03±1x10^-3^                                                                                                                                       
  (n. per MF)                                                                                                                                                                                                      

  I                Occludin\             4.13±0.60             2.58±0.37             4.36±0.48                               [\*](#t001fn002){ref-type="table-fn"}       [\*](#t001fn002){ref-type="table-fn"}     
                   (n. per MF)                                                                                                                                                                                     

  ZO-1\            4.93±1.26             2.62±0.61             3.82±0.93                                                                                                                                           
  (% per MF)                                                                                                                                                                                                       

  Goblet cells\    0.07±8x10^-3^         0.07±4x10^-3^         0.06±7x10^-3^                                                                                                                                       
  (n. per MF)                                                                                                                                                                                                      

  C                Occludin\             2.39±0.23             2.35±0.30             2.45±0.29                                                                                                                     
                   (% per MF)                                                                                                                                                                                      

  ZO-1\            16.02±1.28            14.98±0.79            14.62±1.24                                                                                                                                          
  (% per MF)                                                                                                                                                                                                       

  Goblet cells\    407±33.54             346±27.18             350±19.80                                                                                                                                           
  (n. per MF)                                                                                                                                                                                                      

  F                Acetic acid\          126±8.39              106±8.14              121±11.82                                                                                                                     
                   (μmol/g)                                                                                                                                                                                        

                   Propionic acid\       12.83±1.43            16.81±1.42            15.45±1.87                                                                                                                    
                   (μmol/g)                                                                                                                                                                                        

                   Butyric acid\         9.85±1.38             13.61±1.06            14.87±1.65                                                                                                                    [\*](#t001fn002){ref-type="table-fn"}
                   (μmol/g)                                                                                                                                                                                        
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

All data are expressed as means ± SEM. Group sizes: C (n = 10), PERM (n = 10) and PERM+ERW (n = 10). MPO, myeloperoxidase; n, number of positive cells stained; A, absorbance; MF, microscopic field; NAS, non-alcoholic fatty liver disease activity score.

\*P\<0.05

\*\*P\<0.01

\*\*\*P\<0.001

Immunohistochemical findings in duodenum, ileum and colon and iNOS protein levels in liver tissue {#sec017}
-------------------------------------------------------------------------------------------------

To further delineate if the increased permeability of FITC-dextran was related to a loss of tight junction proteins in the small or large intestine, protein levels of ZO-1 and occludin were determined in duodenum, ileum and colon ([Fig 2B](#pone.0223238.g002){ref-type="fig"} and [Table 1](#pone.0223238.t001){ref-type="table"}). Occludin protein levels were significantly lower in PERM-treated rats when compared to controls and did not differ from those of PERM+ERW-treated animals (P\>0.05) in duodenum. Moreover, ZO-1 protein concentration was significantly lower in duodenum of PERM-treated rats and PERM+ERW-treated animals when compared to controls. In ileum of PERM-treated rats protein, levels of occludin were significantly lower than in all other groups (P\<0.05 for both) while protein levels of ZO-1 were similar among groups in this part of the small intestine. Neither protein levels of ZO-1 nor occludin differed between groups in colon. Also, the number of goblet cells was similar among groups in all three parts of small and large intestine studied.

As it has been suggested before that an increased intestinal permeability and subsequently elevated translocation of bacterial endotoxin leads to an induction of iNOS in the liver \[[@pone.0223238.ref029]\], \[[@pone.0223238.ref018]\], protein levels of iNOS were determined in liver tissue ([Fig 2A](#pone.0223238.g002){ref-type="fig"} and [Table 1](#pone.0223238.t001){ref-type="table"}). In line with the findings for liver histology but also for markers of intestinal permeability, iNOS protein levels were significantly higher in livers of PERM-treated rats than in those of PERM+ERW animals and controls. Levels of iNOS protein did not differ between PERM+ERW-treated rats and controls (P\>0.05).

Levels of SCFA in feces {#sec018}
-----------------------

Results revealed no significant difference (F~(2,27)~ = 1.15, P\>0.05; F~(2,27)~ = 1.62, P\>0.05) among control, PERM-treated and PERM+ERW-treated groups for acetic and propionic acid levels in the feces, as shown in [Table 1](#pone.0223238.t001){ref-type="table"}. On the other hand, different levels of butyric acid levels (F~(2,27)~ = 3.55, P\<0.05) were measured among the three groups. Post hoc analysis revealed that butyric acid was significantly higher in PERM+ERW-treated group than in controls (P *=* 0.041). These results showed that co-treatment in early life with ERW may be able to increase the population of butyric acid producing bacteria.

Microbiota composition in feces {#sec019}
-------------------------------

Thirty fecal samples collected at PND 60 were evaluated using 16S rRNA gene sequencing to determine the composition of the fecal bacterial populations in 10 control, 10 PERM-treated and 10 PERM+ERW-treated rats. To determine the bacterial community diversity in samples, we calculated Chao and Shannon indexes ([Fig 3](#pone.0223238.g003){ref-type="fig"}). Both indexes, which are calculated based on the number and distribution of OTUs, showed statistical differences among groups. The samples belonging to PERM+ERW-treated group showed higher Chao1 index compared to those of PERM-treated group (P = 0.004) and higher Shannon index compared with those of PERM-treated and control groups (P = 0.016 and P = 0.045, respectively).

![Significance of alpha diversity estimators in fecal microbiota of 2-month-old rats treated in early life with vehicle (C), permethrin (PERM) or permethrin+electrolyzed reduced water (PERM+ERW).\
Each group is made of n = 10 animals. \*P\<0.05; \*\*P\<0.01.](pone.0223238.g003){#pone.0223238.g003}

Principal coordinates analysis (PCoA) showed a significant difference in bacterial composition between PERM and PERM+ERW groups. In fact, the subjects of the two groups formed distinct clusters, based on the first two principal component scores, which accounted for 41.63% and 11.88% of the total variations, respectively ([Fig 4](#pone.0223238.g004){ref-type="fig"}). On the contrary, there was substantial overlap between control and the other two groups, and most control samples were positioned in the middle of the PERM and PERM+ERW clusters.

![Comparison of variation in fecal microbiota of 2-month-old rats treated in early life with vehicle (Control), permethrin (PERM) or permethrin+electrolyzed reduced water (PERM+ERW).\
Principal coordinate plot of weighted UniFrac distances between fecal samples. Each dot represents a sample: red, Control; blu, PERM; orange, PERM+ERW.](pone.0223238.g004){#pone.0223238.g004}

Looking at microbial abundance after early life treatment with vehicle, PERM or PERM+ERW, we observed differences among groups at the family and genus levels as shown in supplementary [S1 Table](#pone.0223238.s002){ref-type="supplementary-material"}. Phyla *Firmicutes* and *Bacteroidetes* were the most abundant in all animals. In both control and PERM groups, *Bacteroidetes* were more abundant than in the PERM+ERW group (P\<0.01), whereas *Firmicutes* were more abundant in the PERM+ERW group (P\<0.01). Moreover, the latter exhibited higher abundances of phylum *Proteobacteria* compared to the other groups (P\<0.05) for the presence of higher percentage of genus *Desulfovibrio* belonging to this phylum.

A total of 57 genera identified from all samples are shown in detail in [S1 Table](#pone.0223238.s002){ref-type="supplementary-material"} and the heatmap exhibits the distribution of the top abundant genera among all samples ([S1 Fig](#pone.0223238.s001){ref-type="supplementary-material"}). The 6 most abundant genera, containing more than 85% of the total sequences, were *Prevotella*, *U*.*m*. *of S24-7 family*, *Lactobacillus*, *Blautia*, *U*.*m*. *of Lachnospiraceae family* and *U*.*m*. *of Ruminococcaceae family*. Of them, *U*.*m*. *of Prevotellaceae family* and *U*.*m*. *of S24-7 family* were members of the phylum *Bacteroidetes*, whereas the other 4 genera belong to the phylum *Firmicutes*. Among the 6 most abundant genera, the fecal microbiota of PERM+ERW group exhibited significantly lower abundances of *U*.*m*. *of S24-7 family* (P\<0.05) and higher abundances of *Blautia* (P\<0.01), *U*.*m*. *of Lachnospiraceae family* (P\<0.05) and *U*.*m*. *of Ruminococcaceae family* (P\<0.01) than the other two groups as showed in [Fig 5](#pone.0223238.g005){ref-type="fig"}.

![Relative abundance of 6 most predominant bacterial genera (relative abundance ≥ 85% in sample) in fecal microbiota of 2-month-old rats treated in early life with vehicle (Control), permethrin (PERM) or permethrin+electrolyzed reduced water (PERM+ERW).\
All data are expressed as means ± SEM. Each group is made of n = 10 animals. \*P\<0.05; \*\*P\<0.01.](pone.0223238.g005){#pone.0223238.g005}

Among the other less abundant genera, differences between control and PERM groups were observed for *Lachnospira* resulting less abundant (P\<0.05) and *Defluviitaleaceae* resulting more abundant in the PERM group (P\<0.05), whereas the co-treatment with ERW was protective against PERM treatment since that the abundance in *Lachnospira* (P\>0.05 *vs* control group) and *Defluviitaleaceae* (P\>0.05) was similar than in the control group. Other potentially important butyrate producers were increased in the PERM+ERW group compared to the other two groups, such as *Roseburia* (P\<0.01 *vs* PERM group), *Oscillibacter* (P\<0.01 *vs* PERM group), *Intestinimonas* (P\<0.05 vs PERM group), *Papillibacter* (P\<0.01 *vs* PERM group, P\<0.05 *vs* control group) and *Shuttleworthia* (P\<0.05 *vs* PERM group).

Discussion {#sec020}
==========

ERW produced from tap water by electrolyzing device exhibits low dissolved oxygen, extremely high dissolved molecular hydrogen, and most importantly, shows ROS scavenging activity and protective effects against oxidative damage as demonstrated in a MPTP mouse model of Parkinson's disease \[[@pone.0223238.ref030]\]. A clinical study shows that the negative ORP of ERW creates a gut environment by which protective microbiota, especially anaerobic bacteria, thrives allowing a protection against pathogenic bacteria in patients with irritable bowel syndrome \[[@pone.0223238.ref031]\].

In a preliminary study, we demonstrated that perinatal oral exposure to PERM pesticide could negatively affect the fecal microbiota and could be a crucial factor contributing to the development of PD in this animal model \[[@pone.0223238.ref022]\].

In this study, we attempted to further elucidate the effect of ERW co-treatment in the same animal model of PD focusing on intestinal permeability, fecal microbiota composition and histological hallmarks of hepatic injury measured 40 days after the last treatment (PND 60).

The main finding emerged from this study concerns the increased gut permeability, measured by FITC-dextran assay, in PERM group compared to control group. The fact that elevated permeability was not observed in PERM+ERW group indicated that ERW co-treatment was effective to protect the intestinal barrier against the damage induced by PERM. Since increased intestinal permeability often involves a disruption of the tight junction proteins, their expression in duodenum, ileum and colon was measured. In duodenum, a decrease of occludin and ZO-1 protein levels in PERM-treated rats when compared to controls was observed, whereas animals co-treated with ERW did not shown an improvement. The protective effect of ERW co-treatment against PERM-induced intestinal permeability was observed in the ileum, where protein levels of occludin were higher than those measured in PERM-treated rats similarly to those of controls. Since defective mucus barrier resulting from depletion of goblet cells seems to be associated with increased intestinal permeability, we measured the number of goblets cells in the duodenum, ileum and colon. However, no significant differences were observed among groups in all three parts of small and large intestine.

Histological hallmarks of hepatic inflammation were investigated in the animals at PND 60. Inflammatory reactions in the liver often appear concurrently to a translocation of bacteria and their products across the leaky intestinal barrier to the liver. In line with the increased permeability of FITC-dextran, hepatic inflammation, number of neutrophils and iNOS protein levels were higher in livers of PERM-treated rats than in those of PERM+ERW animals and controls. The results, here obtained, allow us to postulate a first hypothesis: the ERW co-treatment in early life could protect intestinal barrier and then prevent liver damage. However, the intestinal barrier acts as a shield which can be modified by the gut microbiota and its metabolites such as the SCFA. In order to verify the hypothesis that the positive effects of ERW co-treatment observed in rats treated with PERM were linked to changes on gut microbiota, we firstly determined the levels of fecal SCFA and secondly the composition of the fecal bacterial populations. The significant increase of butyric acid levels measured in feces of PERM+ERW rats may explain in part the positive role played by ERW on gut microbiota. As demonstrated by many studies, the action of butyric acid extends beyond energy source for colonocytes, playing a role in the down regulation of the expression of pro-inflammatory mediators such as nitric oxide, interleukin-6, and interleukin-12 in intestinal macrophages \[[@pone.0223238.ref032]\], \[[@pone.0223238.ref033]\].

To evaluate PERM+ERW administration effects on gut microbial composition, we compared the relative abundance of the entire detected taxa in each group. Our investigation of alpha diversity, for quantifying the bacterial component and relative richness of a specific community, revealed an elevation of diversity estimators (Shannon and Chao indexes) in the PERM+ERW group compared to the PERM group suggesting that a rich diversity of gut microbiota may be related to the co-treatment with ERW. Hierarchical clustering and PCoA analysis of beta diversity was able to discriminate PERM samples from PERM+ERW samples, whereas control samples were positioned in the middle of the PERM and PERM+ERW samples.

At the phylum level, in the PERM+ERW group, the proportion of *Firmicutes* increased and the proportion of *Bacteroidetes* decreased significantly (P\<0.01) compared with those of the other two groups. Moreover, *Proteobacteria* community, present at low levels in the control and PERM groups, were enriched in the PERM+ERW group (P\<0.05) for the presence of higher abundance of genus *Desulfovibrio* belonging to this phylum. At the genus level, differences between control and PERM groups were observed for *Lachnospira* resulting less abundant (P\<0.05) and *Defluviitaleaceae* resulting more abundant in the PERM group (P\<0.05), whereas the co-treatment with ERW was protective against PERM treatment since that the abundances in *Lachnospira* (P\>0.05) and *Defluviitaleaceae* (P\>0.05) were similar to those in the control group. We speculate that these two communities might be considered as specific biomarkers in our animal model of Parkinson's disease. Prior literature indicates that lower *Lachnospira* and higher *Defluviitaleaceae* abundances were reported in an animal model with indomethacin-induced enteropathy \[[@pone.0223238.ref034]\].

Other significant differences in microbiota composition were associated to ERW co-treatment: higher abundances of *Blautia* (P\<0.01 *vs* PERM and control group), *U*.*m*. *of Lachnospiraceae family* (P\<0.05 *vs* PERM and control group*)*, *U*.*m*. *of Ruminococcaceae family (P\<0*.*01 vs* PERM and control group*)*, *Papillibacter* (P\<0.01 *vs* PERM group, P\<0.05 *vs* control group) were found in PERM+ERW group. Moreover, higher abundances of *Roseburia* (P\<0.01), *Oscillibacter* (P\<0.01), *Intestinimonas* (P\<0.05) and *Shuttleworthia* (P\<0.05) were found in the fecal samples of PERM+ERW group compared to PERM group. Most of these bacteria are important butyrate producers and this result is consistent with the higher butyric acid levels measured in the fecal samples of PERM+ERW group. Among these bacteria, *Blautia*, *U*.*m*. *of Lachnospiraceae family*, *U*.*m*. *of Ruminococcaceae family*, *Papillibacter*, *Roseburia*, *Intestinimonas*, *Shuttleworthia* are Firmicutes members belonging to *Clostridium* and they are obligate anaerobes producing butyrate as major products from the fermentation of non-digestible carbohydrates in the colon \[[@pone.0223238.ref035]\]. Changes in the gut environment such as carbon source availability and hydrogen partial pressure have a major role in shaping the composition and activity of the bacterial community \[[@pone.0223238.ref036]\], \[[@pone.0223238.ref037]\]. The results, here obtained, allow us to hypothesize that the co-treatment with ERW, a drinking water rich in hydrogen, could favour the growth of anaerobes by lowering the redox potential in the intestinal lumen. Data in the literature can support this idea: ERW with negative ORP value between -300 and -400 mV is the optimum range favouring the growth of strict anaerobes in the gut \[[@pone.0223238.ref038]\], \[[@pone.0223238.ref039]\].

On the other hand, the co-treatment with ERW increased significantly the abundances of *Desulfovibrio*, a sulfate-reducer strict anaerobe that utilizes hydrogen as electron donor to produce hydrogen sulfide (H~2~S). At excessive concentrations, sulfide exerts pro-inflammatory effects on the colonic mucosa whereas at lower concentrations is used as energy substrate by colonocytes \[[@pone.0223238.ref040]\]. Considering that rats were co-treated twice a day with 10 mL/kg of ERW, we must point out that higher dosage could negatively affect colonic epithelial barrier.

In conclusion, our animal model of permethrin-induced Parkinson's disease \[[@pone.0223238.ref001]\] showed increased intestinal permeability together with hepatic inflammation correlated with altered gut microbiota. The positive effects of ERW co-treatment observed in gut, liver and brain of rats were linked to changes on gut microbiota. This study demonstrates that the co-treatment with a functional drinking water, could create a gut environment favourable for the fermentation process producing butyric acid. Food-base therapy such as ERW drinking or/and a diet rich in natural sources of butyrate is a highly appealing approach that, if validated, may be used in conjunction with traditional pharmacological treatments to improve outcomes in patients with brain disorders.

Further studies in germ-free mice are needed to characterize the precise mechanism by which these microbes affect the host physiology.
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###### Changes in fecal microbiota of 2-month-old rats treated in early life with vehicle (Control), permethrin (PERM) or permethrin+electrolyzed reduced water (PERM+ERW).

The heat map shows the relative abundance of bacterial genera identified in each sample, the three groups (n = 10 rats per group) are separated by green lines. Hierarchical clustering was performed using Pearson correlation.

(TIF)

###### 

Click here for additional data file.

###### Relative abundance of bacterial genera in fecal microbiota.

Relative abundance of bacterial genera in fecal microbiota of 2-months-old rats treated in early life with vehicle (C), permethrin (PERM) or permethrin+electrolyzed reduced water (PERM+ERW). All data are expressed as means ± SEM. Group sizes: control (n = 10), PERM (n = 10) and PERM+ERW (n = 10). Significance was determined using Kruskal-Wallis (^a^) or ANOVA (^b^). **\***P\<0.05; **\*\***P\<0.01; **\*\*\***P\<0.001.

(PDF)

###### 

Click here for additional data file.
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